0.6211

1.41% -0.0089

After Hours: .6297 0.0086 +1.38%

Galecto Inc (GLTO)

Overview News Price History Option Chain Financials Discussions Forecast

Galecto Inc stock is currently priced at $0.6211, with a 24-hour trading volume of 44,139. It has seen a -1.41% decreased in the last 24 hours and a -7.90% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.6289 pivot point. If it approaches the $0.6128 support level, significant changes may occur.

Previous Close:

$0.63

Open:

$0.6302

24h Volume:

44,139

Market Cap:

$16.84M

Revenue:

Net Income/Loss:

$-38.35M

P/E Ratio:

-0.309

EPS:

-2.01

Net Cash Flow:

$-36.91M

1W Performance:

-8.63%

1M Performance:

-7.90%

6M Performance:

+1.54%

1Y Performance:

-73.05%

1D Range:

$0.6157

$0.6304

52W Range:

$0.50

$3.70

Galecto Inc Stock (GLTO) Company Profile

Name

Galecto Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

457 070 5210

Address

75 State Street, Suite 100, Boston

Employee

Twitter

Next Earnings Date

2024-04-29

Latest SEC Filings

GLTO's Discussions on Twitter

Galecto Inc Stock (GLTO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-26-21	Resumed	Credit Suisse	Outperform
Nov-23-20	Initiated	BofA Securities	Buy
Nov-23-20	Initiated	Credit Suisse	Outperform
Nov-23-20	Initiated	SVB Leerink	Outperform

Galecto Inc Stock (GLTO) Latest News

Galecto (GLTO) Down 71% as Lung Disease Candidate Fails - Yahoo New Zealand News

Yahoo New Zealand News

Galecto, Inc. (GLTO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Singapore News

Yahoo Singapore News

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

GlobeNewswire Inc.

Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 ... - PR Newswire

PR Newswire

GLTO Stock Quote Price and Forecast - CNN

CNN

Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zacks Investment Research

Galecto Inc Stock (GLTO) Financials Data

Galecto Inc (GLTO) Net Income 2024

GLTO net income (TTM) was -$38.35 million for the quarter ending December 31, 2023, a +37.77% increase year-over-year.

Galecto Inc (GLTO) Cash Flow 2024

GLTO recorded a free cash flow (TTM) of -$36.91 million for the quarter ending December 31, 2023, a +14.42% increase year-over-year.

Galecto Inc (GLTO) Earnings per Share 2024

GLTO earnings per share (TTM) was -$1.45 for the quarter ending December 31, 2023, a +40.33% growth year-over-year.

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.